维奈托克、达沙替尼和FLT3抑制剂联合治疗NUP98-NSD1+/FLT3-ITD+急性髓系白血病：一例儿科病例报告。 - Suppr

Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia: A pediatric case report.

作者信息

Wen Xiaojia, Wu Ying, Huang Pengli, Zheng Huyong

机构信息

Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing, China.

National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Capital Medical University, Beijing, China.

出版信息

Pediatr Blood Cancer. 2023 Jul;70(7):e30308. doi: 10.1002/pbc.30308. Epub 2023 Mar 25.

DOI:10.1002/pbc.30308

PMID:36965174

Abstract

摘要

相似文献

Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia: A pediatric case report.维奈托克、达沙替尼和FLT3抑制剂联合治疗NUP98-NSD1+/FLT3-ITD+急性髓系白血病：一例儿科病例报告。

Pediatr Blood Cancer. 2023 Jul;70(7):e30308. doi: 10.1002/pbc.30308. Epub 2023 Mar 25.

NUP98::NSD1 and FLT3/ITD co-expression is an independent predictor of poor prognosis in pediatric AML patients.NUP98::NSD1 和 FLT3/ITD 共表达是儿科急性髓系白血病患者预后不良的独立预测因子。

BMC Pediatr. 2024 Aug 24;24(1):547. doi: 10.1186/s12887-024-05007-3.

Dasatinib and navitoclax act synergistically to target NUP98-NSD1/FLT3-ITD acute myeloid leukemia.达沙替尼和 navitoclax 协同作用靶向 NUP98-NSD1/FLT3-ITD 急性髓系白血病。

Leukemia. 2019 Jun;33(6):1360-1372. doi: 10.1038/s41375-018-0327-2. Epub 2018 Dec 19.

Successful treatment of acute myeloid leukemia co-expressing NUP98/NSD1 and FLT3/ITD with preemptive donor lymphocyte infusions.成功治疗同时表达 NUP98/NSD1 和 FLT3/ITD 的急性髓系白血病，采用抢先性供者淋巴细胞输注。

Int J Hematol. 2019 Oct;110(4):512-516. doi: 10.1007/s12185-019-02665-3. Epub 2019 May 27.

Pediatric acute myeloid leukemia co-expressing FLT3/ITD and NUP98/NSD1 treated with gilteritinib plus allogenic peripheral blood stem cell transplantation: A case report.吉列替尼联合异基因外周血干细胞移植治疗共表达FLT3/ITD和NUP98/NSD1的小儿急性髓系白血病：一例报告

Pediatr Blood Cancer. 2021 Nov;68(11):e29216. doi: 10.1002/pbc.29216. Epub 2021 Jul 10.

Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML.NUP98::NSD1融合在成人FLT3-ITD阳性急性髓系白血病诊断时的临床意义

Eur J Haematol. 2023 Oct;111(4):620-627. doi: 10.1111/ejh.14055. Epub 2023 Jul 19.

NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR.NUP98-NSD1 融合伴 FLT3-ITD 突变可识别出适合实时定量 PCR 监测的具有预后意义的小儿急性髓系白血病亚组。

Genes Chromosomes Cancer. 2013 Nov;52(11):1053-64. doi: 10.1002/gcc.22100. Epub 2013 Sep 2.

Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction.NUP98-NSD1融合蛋白与FLT3-ITD突变在急性髓系白血病诱导中的强力协同作用。

Haematologica. 2014 Sep;99(9):1465-71. doi: 10.3324/haematol.2013.100917. Epub 2014 Jun 20.

Acute myeloid leukemia patients with NUP98::NSD1 showing initially poor treatment response can benefit from FLT3 inhibitors and venetoclax as well as HSCT.初治反应不佳的伴有NUP98::NSD1的急性髓系白血病患者可从FLT3抑制剂、维奈克拉以及异基因造血干细胞移植中获益。

Ann Hematol. 2023 Feb;102(2):473-475. doi: 10.1007/s00277-022-05047-8. Epub 2022 Nov 24.

Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.FLT3-ITD阳性急性髓系白血病患儿的风险分层治疗：日本儿科白血病/淋巴瘤研究组（JPLSG）AML-05研究结果

Int J Hematol. 2018 May;107(5):586-595. doi: 10.1007/s12185-017-2395-x. Epub 2018 Jan 12.

引用本文的文献

From low remission to hope: the efficacy of targeted therapies in NUP98-R positive pediatric acute myeloid leukemia.从低缓解率到希望：靶向治疗在NUP98-R阳性儿童急性髓系白血病中的疗效

World J Pediatr. 2025 Mar;21(3):266-273. doi: 10.1007/s12519-025-00875-w. Epub 2025 Feb 27.

Monocentric experience of venetoclax-based regimen in paediatric refractory and relapsed AML/MDS.基于维奈托克方案治疗儿童难治性和复发性急性髓系白血病/骨髓增生异常综合征的单中心经验

Br J Haematol. 2025 Jan;206(1):209-214. doi: 10.1111/bjh.19849. Epub 2024 Oct 24.

NUP98 oncofusions in myeloid malignancies: An update on molecular mechanisms and therapeutic opportunities.髓系恶性肿瘤中的NUP98致癌融合：分子机制与治疗机会的最新进展

Hemasphere. 2024 Sep 25;8(9):e70013. doi: 10.1002/hem3.70013. eCollection 2024 Sep.

The landscape of NUP98 rearrangements clinical characteristics and treatment response from 1491 acute leukemia patients.1491例急性白血病患者的NUP98重排的临床特征及治疗反应情况

Blood Cancer J. 2024 May 14;14(1):81. doi: 10.1038/s41408-024-01066-y.

Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies?维奈托克：高危髓系恶性肿瘤患儿治疗的新选择？

Blood Adv. 2024 Jul 9;8(13):3583-3595. doi: 10.1182/bloodadvances.2023012041.

Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies. Venetoclax 联合疗法在儿科血液系统恶性肿瘤中的最新进展。

Int J Mol Sci. 2023 Nov 24;24(23):16708. doi: 10.3390/ijms242316708.

Redefining Cancer Therapy: Toward BCL-XL/BCL-2 Dual Inhibitors with Diminished Platelet Toxicity.重新定义癌症治疗：迈向血小板毒性降低的BCL-XL/BCL-2双重抑制剂

ACS Med Chem Lett. 2023 Aug 22;14(9):1156-1158. doi: 10.1021/acsmedchemlett.3c00357. eCollection 2023 Sep 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia: A pediatric case report.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献